Press Releases

Date Title and Summary View
Aug 31, 2017
MacroGenics Announces Termination of Duvortuxizumab Collaboration and License Agreement with Janssen

Development of MGD015 (JNJ-9383) to continue by Janssen

Additional Formats
Aug 30, 2017
MacroGenics to Participate in Three Investor Conferences in September
ROCKVILLE, MD, Aug. 30, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Aug 09, 2017
MacroGenics to Present at the Wedbush PacGrow Healthcare Conference
ROCKVILLE, MD, Aug. 09, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Aug 02, 2017
MacroGenics Provides Update on Corporate Progress and Second Quarter 2017 Financial Results
ROCKVILLE, Md., Aug. 02, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Jul 26, 2017
MacroGenics Announces Date of Second Quarter 2017 Financial Results Conference Call
ROCKVILLE, MD , July 26, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, August 2, 2017 , the Company will release its financial results for the quarter ended June 30, 2017 . The Company's management team will host a conference call discussing the
Additional Formats
Jul 17, 2017
Phase 1 Data for Flotetuzumab, MacroGenics' CD123 x CD3 DART® Molecule, Accepted for Oral Presentation at ESMO Congress 2017
ROCKVILLE, MD , July 17, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Jun 17, 2017
MacroGenics Presents Updated Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2017)

Single dose administration of CD32B x CD79B bispecific DART® molecule delivers an immunomodulatory effect that counters B-cell function

Additional Formats
May 03, 2017
MacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results
ROCKVILLE, Md., May 03, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Apr 27, 2017
MacroGenics Announces Registered Direct Offering of Common Stock
Rockville, MD, April 27, 2017 (GLOBE NEWSWIRE) -- --  MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Apr 26, 2017
MacroGenics to Present at Two Upcoming Investor Conferences in May
Rockville, MD, April 26, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Apr 25, 2017
MacroGenics Announces Date of First Quarter 2017 Financial Results Conference Call
ROCKVILLE, MD , April 25, 2017 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, May 3, 2017 , the Company will release its financial results for the quarter ended March 31, 2017 . The Company's management team will host a conference call discussing the
Additional Formats
Mar 31, 2017
Eight Posters Based on MacroGenics-developed Molecules Featured at AACR Annual Meeting 2017
Rockville, MD, March 31, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Mar 29, 2017
MacroGenics to Present at the Needham Healthcare Conference
Rockville, MD, March 29, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Feb 28, 2017
MacroGenics Provides Update on Corporate Progress and 2016 Financial Results
ROCKVILLE, Md., Feb. 28, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Feb 27, 2017
MacroGenics to Participate in Two Upcoming Investor Conferences
Rockville, MD, Feb. 27, 2017 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Feb 16, 2017
MacroGenics Announces Date of Fourth Quarter and Full Year 2016 Financial Results Conference Call
ROCKVILLE, MD, Feb. 16, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Feb 09, 2017
MacroGenics to Present at the Leerink Partners 6th Annual Global Healthcare Conference
ROCKVILLE, MD, Feb. 09, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Jan 25, 2017
MacroGenics Announces Appointments to Board of Directors
Rockville, MD , Jan. 25, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Jan 05, 2017
MacroGenics' MGD006 Granted Orphan Drug Status for AML by FDA
ROCKVILLE, MD , Jan. 05, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Jan 05, 2017
MacroGenics to Present at the 35th Annual J.P. Morgan Healthcare Conference
ROCKVILLE, MD, Jan. 05, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Dec 13, 2016
MacroGenics Highlights Progress at 2016 R&D Day
Advancement of HER2 franchise led by margetuximab Expansion and progression of B7-H3 franchise Introduction of PD-1 directed immuno-oncology franchise Clinical updates on multiple DART® studies underscore platform progress Pipeline poised to expand with at least 3 new INDs from internal R&D in
Additional Formats
Dec 12, 2016
MacroGenics Licenses Synthon's Technology to Develop an Anti-B7-H3 ADC
ROCKVILLE, Md. and NIJMEGEN, the Netherlands, Dec. 12, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune
Additional Formats
Dec 08, 2016
MacroGenics to Host 2016 R&D Day

Company to provide in-depth review of its antibody-based technology platforms and broad portfolio of therapeutics being developed to treat cancer, autoimmune disorders and infectious diseases

Additional Formats
Nov 02, 2016
MacroGenics Provides Update on Corporate Progress and Third Quarter 2016 Financial Results
Continued expansion and advancement of product candidates Portfolio update planned for upcoming R&D Day on December 13, 2016 ROCKVILLE, Md., Nov. 02, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative
Additional Formats
Nov 01, 2016
MacroGenics to Participate in Two Upcoming Investor Conferences
Rockville, MD, Nov. 01, 2016 (GLOBE NEWSWIRE) -- --  MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats